Atopic Dermatitis Drugs: Global Strategic Business Report

Global Atopic Dermatitis Drugs Market to Reach $38.4 Billion by 2030

The global market for Atopic Dermatitis Drugs estimated at US$8.1 Billion in the year 2022, is projected to reach a revised size of US$38.4 Billion by 2030, growing at a CAGR of 21.4% over the analysis period 2022-2030. Biologics, one of the segments analyzed in the report, is projected to record 23% CAGR and reach US$18.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Corticosteroids segment is readjusted to a revised 21.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2.1 Billion, While China is Forecast to Grow at 27.2% CAGR

The Atopic Dermatitis Drugs market in the U.S. is estimated at US$2.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$10.5 Billion by the year 2030 trailing a CAGR of 27.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 16.1% and 19.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 17.9% CAGR.

Select Competitors (Total 12 Featured) -

• Allergan Plc
• Anacor Pharmaceutical Inc.
• Astellas Pharma, Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• Encore Dermatology
• Leo Pharma
• Meda Pharmaceuticals
• Mylan
• Novartis International AG
• Pfizer
• Regeneron Pharmaceuticals, Inc.
• Sanofi
• Valent Pharmaceutical Inc.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year